Investors Purchase High Volume of Call Options on DaVita (NYSE:DVA)

DaVita Inc. (NYSE:DVA) was the target of some unusual options trading activity on Friday. Stock traders bought 6,418 call options on the stock. This is an increase of 884% compared to the average volume of 652 call options.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of research reports. Truist Financial set a $140.00 target price on shares of DaVita in a research report on Tuesday, October 14th. Bank of America decreased their price objective on DaVita from $145.00 to $140.00 and set an “underperform” rating for the company in a report on Wednesday, September 10th. Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday. Zacks Research upgraded DaVita from a “strong sell” rating to a “hold” rating in a research report on Friday, November 28th. Finally, Barclays decreased their price target on DaVita from $149.00 to $143.00 and set an “equal weight” rating for the company in a report on Thursday, October 30th. One investment analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $148.00.

Institutional Trading of DaVita

Several large investors have recently bought and sold shares of the business. Arrowstreet Capital Limited Partnership lifted its stake in DaVita by 109.7% in the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 553,809 shares of the company’s stock worth $73,585,000 after purchasing an additional 289,725 shares in the last quarter. Man Group plc lifted its position in DaVita by 1,608.6% during the second quarter. Man Group plc now owns 285,809 shares of the company’s stock worth $40,713,000 after buying an additional 269,081 shares in the last quarter. Neuberger Berman Group LLC lifted its position in DaVita by 138.5% during the third quarter. Neuberger Berman Group LLC now owns 463,250 shares of the company’s stock worth $61,502,000 after buying an additional 269,015 shares in the last quarter. Norges Bank purchased a new stake in DaVita in the 2nd quarter valued at $32,986,000. Finally, Voloridge Investment Management LLC grew its holdings in DaVita by 2,905.7% in the 3rd quarter. Voloridge Investment Management LLC now owns 228,221 shares of the company’s stock valued at $30,324,000 after buying an additional 220,628 shares in the last quarter. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

DaVita stock opened at $115.18 on Friday. The stock has a market capitalization of $8.13 billion, a PE ratio of 11.86, a price-to-earnings-growth ratio of 0.88 and a beta of 1.00. The business has a 50 day simple moving average of $121.38 and a 200-day simple moving average of $131.48. DaVita has a 12 month low of $113.97 and a 12 month high of $179.60.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $3.17 by ($0.66). The company had revenue of $3.42 billion during the quarter, compared to analysts’ expectations of $3.43 billion. DaVita had a net margin of 5.80% and a negative return on equity of 13,370.89%. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same period in the prior year, the business posted $2.59 earnings per share. DaVita has set its FY 2025 guidance at 10.350-11.150 EPS. On average, equities research analysts anticipate that DaVita will post 10.76 EPS for the current fiscal year.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.